放射性药物治疗对肾功能的影响
放射性药物治疗(RPT)对肾功能的影响通常被认为较低,但使用生长抑素放射性药物的肽受体放射性核素治疗(PRRT),尤其是90Y-DOTATOC,可能引起肾毒性,因其主要经肾小球滤过并在近端小管重吸收。氨基酸共输注是竞争性抑制小管重吸收的标准方案,其他保护措施包括水化、使用血浆扩容剂或辐射防护剂、个性化肾脏剂量学及密切监测肾功能。有限数据提示α发射体PRRT对肾功能影响小于β发射体PRRT,但需更多长期肾毒性研究;131I-MIBG经肾排泄但肾脏吸收剂量低,骨髓和肺毒性是主要临床关注点。
要点
- PRRT放射性药物主要经肾小球滤过,近端小管重吸收增加肾脏辐射暴露。
- 氨基酸共输注是竞争性抑制小管重吸收、减轻肾毒性的标准方案。
- 有限数据提示α发射体PRRT对肾功能影响小于β发射体PRRT,需更多长期研究。
核心结论
- RPT对肾功能的影响通常被认为较低,但使用生长抑素放射性药物的PRRT,尤其是90Y-DOTATOC,可能引起肾毒性。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- PRRT放射性药物主要经肾小球滤过清除,其在肾近端小管的重吸收/滞留使肾脏受到额外辐射。
- 有限数据提示α发射体PRRT放射性药物对肾功能的影响小于β发射体PRRT,但需更多研究评估长期肾毒性。
- 131I-MIBG主要经肾脏以原形排泄,但肾脏吸收剂量低,骨髓和肺的潜在毒性是最显著的临床关注点。
- 其他不主要经肾脏清除的RPT如223Ra或放射免疫治疗无肾脏毒性担忧。
关键数值与推荐
- 氨基酸共输注是竞争性抑制PRRT放射性药物小管重吸收以减轻肾毒性的标准方案。
- 保护肾功能的措施包括水化、使用血浆扩容剂或辐射防护剂、限制肾脏辐射剂量的个性化肾脏剂量学以及密切监测肾功能。
临床怎么用
- 原文未据此给出推荐。
局限性
- 有限数据提示α发射体PRRT放射性药物对肾功能的影响小于β发射体PRRT,但需更多研究评估长期肾毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Radiopharmaceuticals used for cancer therapy are highly selective, designed to kill malignant cells and spare healthy tissues. Side effect rates are generally less than other treatments, but it is still the utmost concern to minimize normal organ toxicity and maximize radiation dose to the target lesions in applying radiopharmaceutical therapies (RPTs). Most commonly affected normal organs include bone marrow, kidneys and liver. The impact of RPTs to renal function is generally considered low. Peptide receptor radionuclide therapy (PRRT) using somatostatin radiopharmaceuticals, particularly 90Y-DOTATOC, has the potential to induce nephrotoxicity. This is because PRRT radiopharmaceuticals are primarily cleared thorough glomerular filtration and reabsorption/retainment of them at the renal proximal tubules exposes kidneys to additional radiation. Amino acid co-infusion is the standard regimen for competitive inhibition of tubular reabsorption of PRRT radiopharmaceuticals to mitigate nephrotoxicity. Other measures to protect renal function include hydration, use of plasma expander or radioprotectant, personalized renal dosimetry to limit renal radiation dose and close monitoring of renal function. Limited data suggest alpha emitter PRRT radiopharmaceuticals have less impact on kidney function compared to beta emitter PRRT, but more studies are needed for long term renal toxicity. 131I-MIBG is primarily excreted unchanged thorough the kidneys but renal absorbed dose is low and potential toxicities to the bone marrow and lungs are the most significant clinical concerns. Other RPTs that are not mainly cleared through kidneys such as 223Ra or radioimmunotherapy have no concern for kidney toxicity.
引用
- Park EA, Graves SA, Menda Y, et al. The Impact of Radiopharmaceutical Therapy on Renal Function. Semin Nucl Med. 2022. PMID: 35314056. doi:10.1053/j.semnuclmed.2022.02.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。